Open-source automated insulin delivery

Open-source automated insulin delivery has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Jun 5, 2026: “Beyond Insulin Alone: One-Year CGM Outcomes of Adjunctive Incretin-Based and SGLT2 Inhibitors Therapy in Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems”.

Exposure

1 paper studies it2 findingsUpdated

See all 1 papers on open-source automated insulin delivery

At a glance

The findings reach people, from one lab or study. 1 lab.

“Average Time in Range (TIR) rose from 63% at baseline to 73% at 12 months.”
Beyond Insulin Alone: One-Year CGM Outcomes of Adjunctive Incretin-Based and SGLT2 Inhibitors Therapy in Type 1 Diabetes Using Open-Source Automated Insulin Delivery SystemsADA Scientific Sessions 2026 abstract2026doi:10.2337/db26-1879-p

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab
  • Humans1

What did studies of open-source automated insulin delivery find?

2

Studies of open-source automated insulin delivery measured 2 outcomes: time below range and time in range.

Time below range

no changein humans1

1 study
  1. Open-source automated insulin delivery was not clearly linked with time below range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (averaged 2%).

    Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357

More on Time below range

Time in range

upin humans1

1 study
  1. Open-source automated insulin delivery is linked with higher time in range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (63% to 73% at 12 months).

    Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357

More on Time in range

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months